Evidence map›Paper›PMID 39430289›Full record

ArticleKidney diseases (Basel, Switzerland)2024

Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study.

Meng Wei, Xue Wu, Liteng Wang, Zhichun Gu, Yuanmao Tu, Lihua Zhang, Jiong Zhang, Honglang Xie, Qing Zhou, Yanan Chu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Efficacy and Safety of Direct Oral Anticoagulants Versus Standard Anticoagulation for Thromboprophylaxis in Nephrotic Syndrome: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meng WeiKey Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
Xue WuDepartment of Clinical Pharmacy, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Liteng WangDepartment of Clinical Pharmacy, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Zhichun GuDepartment of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuanmao TuNational Clinical Research Center of Kidney Disease, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Lihua ZhangNational Clinical Research Center of Kidney Disease, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Jiong ZhangNational Clinical Research Center of Kidney Disease, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Honglang XieNational Clinical Research Center of Kidney Disease, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Qing ZhouDepartment of Clinical Pharmacy, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Yanan ChuDepartment of Clinical Pharmacy, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Zhen ChengNational Clinical Research Center of Kidney Disease, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Guohua ZhouDepartment of Clinical Pharmacy, Jinling Hospital Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Qinxin SongKey Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Thromboembolism is a recognized complication of nephrotic syndrome (NS). Evidence supporting the use of rivaroxaban to prevent NS-related thrombosis is limited and controversial. This study aimed to explore the impact of NS on rivaroxaban pharmacokinetics and to collect observational data on the efficacy and safety of rivaroxaban as primary thromboprophylaxis in patients with NS. Methods: This prospective study analyzed 141 patients with NS who received rivaroxaban (10 mg/day) for thromboprophylaxis. High-performance liquid chromatography-tandem mass spectrometry was used to measure the trough and peak plasma concentrations (C Results: The median C Conclusion: Hypoalbuminemia significantly affects the pharmacokinetics of rivaroxaban in NS patients. A dose-adjustment strategy based on rivaroxaban concentrations, accounting for variable albumin levels, may improve the safety and efficacy of thromboprophylaxis in this population.

Indexed as

Gene polymorphismsNephrotic syndromePharmacokineticsRivaroxabanThromboprophylaxis

Identifiers

PMID39430289
PMCPMC11488834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.